To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

Also called NCT07116473

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07116473
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07116473. Allocation not applicable; no masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2037-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Condition
Amyloidosis in Transthyretin (TTR)
Condition
Amyloidosis, Familial
Condition
Amyloid Cardiomyopathy
Condition
Amyloid Cardiomyopathy, Transthyretin-Related
Condition
Amyloidogenic Transthyretin (ATTR) Amyloidosis
Condition
Heart Disease
Condition
Cardiomyopathies
Condition
Amyloidosis, Hereditary, Transthyretin-Related
Condition
Polyneuropathies
Condition
Amyloidosis
Intervention (Drug)
Acoramidis (AG10)
Lead sponsor
Eidos Therapeutics, a BridgeBio company (class: industry)

Record details

Record id
cardio:ct-nct07116473
Content hash
99985d70537c15093f40ee3929752249da4631f2679d0ae543d1b355e6d3947d